US EditionDr. Brian Druker, head of OHSU’s Knight Cancer Institute, steps down: ‘We have ... forgotten our mission’
- Dr. Brian Druker has stepped down as head of the Knight Cancer Institute, but he will continue his research work.
- Dr. Druker mentioned that the school had lost sight of its mission in advancing cancer research.
- OHSU appreciates his leadership and looks forward to working with him in his research and patient care.
5 Articles
5 Articles
OHSU Knight Cancer Institute CEO resigns, claims hospital ‘lost sight of what is crucial’
PORTLAND, Ore. (KOIN) — One of the world's leading cancer researchers is stepping down as CEO of the Knight Cancer Institute at Oregon Health and Science University. Dr. Brian Druker handed in his resignation on Tuesday morning. He cited OHSU's emphasis on finances rather than research and patients as the reason for his resignation. Druker will stay at OHSU but in his lab rather than as the head of the Knight Cancer Institute. Police seek ‘…
Head of OHSU Knight Cancer Institute resigns
OHSU has confirmed that the leader of the Knight Cancer Institute, Dr. Brian Druker, is resigning as CEO. The university said he will continue running his research lab and seeing patients. Druker may be best known for his pioneering work on the cancer drug Gleevec, which dramatically increased the survival rate for a type of leukemia. The drug was one of the first of a group of drugs called “targeted therapies,” designed to attack cancer cells w…
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
